Bortezomib Teva 3.5 mg

/ Abic

The recommended starting dose of Bortezomib is 1.3 mg/m². Bortezomib may be administered intravenously at a concentration of 1 mg/mL, or subcutaneously at a concentration of 2.5 mg/mL. Please refer to the physician prescribing information for reconstitution/preparation for intravenous and subcutaneous administration. When administered intravenously, Bortezomib is administered as a 3 to 5 second bolus intravenous injection.
Because each route of administration has a different reconstituted concentration, caution should be used when calculating the volume to be administered. Bortezomib 3.5 mg is for intravenous or subcutaneous use only. Bortezomib must not be administered by any other route. Intrathecal administration has resulted in death.

Treatment of patients with multiple myeloma. Treatment of patients with mantle cell lymphoma who have received at least one prior therapy. Bortezomib in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.

Patients with hypersensitivity (not including local reactions), anaphylactic reactions to bortezomib, boron, or mannitol. Patients with acute diffuse  infiltrative pulmonary and pericardial disease. Intrathecal administration (due to fatal events).

Please refer to the license holder for further details.